ATE481645T1 - Biomarker für den frühzeitigen nachweis von ovarialkarzinom - Google Patents

Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Info

Publication number
ATE481645T1
ATE481645T1 AT05771584T AT05771584T ATE481645T1 AT E481645 T1 ATE481645 T1 AT E481645T1 AT 05771584 T AT05771584 T AT 05771584T AT 05771584 T AT05771584 T AT 05771584T AT E481645 T1 ATE481645 T1 AT E481645T1
Authority
AT
Austria
Prior art keywords
stage
patients
ovarian
biomarrkers
early detection
Prior art date
Application number
AT05771584T
Other languages
English (en)
Inventor
Robin Farias-Eisner
Srinivasa Reddy
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE481645T1 publication Critical patent/ATE481645T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05771584T 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom ATE481645T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58800704P 2004-07-14 2004-07-14
US67448905P 2005-04-25 2005-04-25
PCT/US2005/024985 WO2006019906A1 (en) 2004-07-14 2005-07-14 Biomarker for early detection of ovarian cancer

Publications (1)

Publication Number Publication Date
ATE481645T1 true ATE481645T1 (de) 2010-10-15

Family

ID=35406265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771584T ATE481645T1 (de) 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Country Status (6)

Country Link
US (3) US8323915B2 (de)
EP (5) EP3203241A1 (de)
AT (1) ATE481645T1 (de)
DE (1) DE602005023629D1 (de)
DK (1) DK2199801T3 (de)
WO (1) WO2006019906A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
RU2313794C1 (ru) * 2006-06-06 2007-12-27 Людмила Васильевна Дикарева Способ дифференциальной диагностики опухолевых процессов яичников
WO2008123948A1 (en) 2007-03-27 2008-10-16 Vermillion, Inc. Biomarkers for ovarian cancer
KR100997463B1 (ko) * 2007-04-30 2010-11-30 (주)예비티 난소암 진단용 조성물, 그 키트 및 진단 방법
RU2334986C1 (ru) * 2007-05-28 2008-09-27 Евгений Григорьевич Шварев Способ ранней диагностики опухолей яичников
WO2009058331A2 (en) * 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CA2818593A1 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
CN103619987B (zh) * 2011-06-10 2016-11-16 巴斯夫欧洲公司 颜色转换器
EP2751126B1 (de) 2011-08-29 2018-03-07 The Regents of The University of California Verwendung von hdl-molekülen zur behandlung und prävention proinflammatorischer leiden
CN105025921B (zh) * 2013-03-15 2019-02-19 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
US20150153348A1 (en) * 2013-12-04 2015-06-04 Vermillion, Inc. BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN
RU2576821C2 (ru) * 2014-06-30 2016-03-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) Способ определения эффективности консервативного лечения рака не увеличенных яичников

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) * 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) * 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
EP1001032A3 (de) 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
SE8904007D0 (sv) * 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DK0553288T3 (da) 1990-10-18 1997-12-29 Cellpro Inc Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
EP1972194A1 (de) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgene Säugetiere mit menschlichen IG-Orten mit mehreren VH- und VK-Regionen und darin erzeugten Antikörpern
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5955582A (en) * 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
WO2000037632A1 (fr) * 1998-12-22 2000-06-29 Daiichi Pure Chemicals Co., Ltd. Anticorps monoclonal dirige contre l'apolipoproteine a-1
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US20050214760A1 (en) * 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
AU2003252136A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
DE60332639D1 (de) 2002-08-06 2010-07-01 Univ Johns Hopkins Verwendung von biomarkern zum nachweis von eierstockkrebs
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US7589174B2 (en) * 2003-05-12 2009-09-15 The Children's Hospital Of Philadelphia GRP94-based compositions and methods of use thereof
EP1658497B1 (de) * 2003-08-25 2008-12-03 Marc Ramael Verfahren und kit zum quantitativen und/oder qualitativen nachweis von komponenten in einer probe
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20050250141A1 (en) * 2004-03-30 2005-11-10 Lambert James L Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
US20060094039A1 (en) * 2004-09-20 2006-05-04 Ron Rosenfeld Diagnosis of fetal aneuploidy
EP1869462B1 (de) * 2005-03-11 2013-05-08 Ciphergen Biosystems, Inc. Biomarker für ovarialkrebs und endometriumkrebs: hepcidin
WO2006121952A2 (en) * 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders

Also Published As

Publication number Publication date
EP2848942A1 (de) 2015-03-18
DK2199801T3 (da) 2013-08-05
US9110083B2 (en) 2015-08-18
DE602005023629D1 (de) 2010-10-28
EP2199801A2 (de) 2010-06-23
EP2261672B1 (de) 2014-09-03
US20130090256A1 (en) 2013-04-11
EP3203241A1 (de) 2017-08-09
EP2199801B1 (de) 2013-05-29
EP2261672A3 (de) 2011-10-05
US20100081151A1 (en) 2010-04-01
EP2848942B1 (de) 2017-03-08
WO2006019906A1 (en) 2006-02-23
EP2261672A2 (de) 2010-12-15
EP1789805A1 (de) 2007-05-30
EP1789805B1 (de) 2010-09-15
EP2199801A3 (de) 2010-08-25
US20160069886A1 (en) 2016-03-10
US8323915B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
DE602005023629D1 (de) Biomarker für den frühzeitigen nachweis von ovarialkarzinom
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Torphy et al. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
Vail et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder
ATE553382T1 (de) Verwendungen von krebsspezifischen glykanen
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
Bernacki et al. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
ATE522620T1 (de) Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
Chen et al. Immunohistochemistry as a quick screening method for clinical detection of BRAF (V600E) mutation in melanoma patients
Chia et al. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors
MY193895A (en) Combination test for colorectal cancer
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
Kato et al. Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
DE60335387D1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
DE602004022632D1 (de) Verwendung von adiponectin zur diagnose von krebs
Banakar et al. Oral squamous cell carcinoma: the role of BIRC6 serum level
Chen et al. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
Rai et al. Association of malignant mesothelioma and asbestos related conditions with ovarian cancer: shared biomarkers and a possible etiological link?
DE60025342D1 (de) Komplex aus n-glykolisierten proteinen (siblings) und faktor h
Talbott et al. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties